SGLT-2 Inhibitor

Revisión del 03:15 18 abr 2017 de Carpenj (discusión | contribs.) (Created page with "==Administration== *Type: Diabetes medication *Canagliflozin (Invokana), Dapagliflozin (Farxiga), empagliflozin (Jardiance) are FDA approved for use in type 2 diabetes ==...")
(difs.) ← Revisión anterior | Revisión actual (difs.) | Revisión siguiente → (difs.)

Administration

  • Type: Diabetes medication
  • Canagliflozin (Invokana), Dapagliflozin (Farxiga), empagliflozin (Jardiance) are FDA approved for use in type 2 diabetes

Contraindications

  • Allergy to class/drug

Adverse Reactions

Serious

  • Euglycemic DKA[1]

Common

  • UTI
  • Genital candidiasis
  • Weight loss
  • Dehydration/Orthostasis

Mechanism of Action

  • Inhibit sodium-glucose cotransporter 2, decreasing glucose reabsorption in the proximal tubule

References

  1. ↑ FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood
Obtenido de «https://www.wikem.org/w/index.php?title=SGLT-2_Inhibitor&oldid=131708»